Treatment Patterns and Economic Outcomes in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US: A Real-World Claims Database Analysis
Author(s)
Doris K. Hansen, MD1, Dhanalakshmi Thirumalai, PhD, MPH2, Constance Lau, MPH2, Ken Hasegawa, PhD2, Monique Giordana, PharmD, BCOP2, Enrique Granados, MD2, Jie Ting, PhD, MSPH3, Rebecca J Chan, MD, PhD3, Taha Itani, PhD, MPH, MBA2.
1H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA, 2Kite, A Gilead Company, Santa Monica, CA, USA, 3Arcellx Inc., Redwood City, CA, USA.
1H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA, 2Kite, A Gilead Company, Santa Monica, CA, USA, 3Arcellx Inc., Redwood City, CA, USA.
OBJECTIVES: Patients with triple-class exposed RRMM, having received proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and anti-CD38 monoclonal antibodies, face substantial clinical and economic burdens that remain poorly understood. This study aims to assess unmet needs in triple-class exposed RRMM by analyzing treatment patterns, healthcare resource utilization (HRU), and associated costs using real-world US claims data.
METHODS: We conducted a retrospective cohort study using the US-based Optum’s de-identified Clinformatics® Data Mart Database (Jan 2015-Mar 2024). Eligible patients were adults with RRMM following at least 3 prior lines of therapy (LOTs) who were triple-class exposed and initiated a new treatment regimen (index LOT). Descriptive statistics summarized treatment patterns and HRU measures. Total cost of care per patient per month (PPPM) was calculated.
RESULTS: A total of 289 patients who initiated 4L+ treatment were included. At index, the median age was 74 years (range: 25-90), and 52.2% were male. Racial distribution was 60.6% White, 16.6% Black, 3.1% Asian, and 20.1% unknown/missing. Patients had received median of 3 prior LOTs (range: 3-7). The median time from diagnosis to index LOT was 34 months and median follow up from index LOT was 8 months (IQR 3-15). Total costs PPPM rose from $21,336 in 1L to $30,331 in 4L+. Similarly, PPPM costs for all-cause hospitalizations increased from $2,670 in 1L to $3,814 in 4L+. More than half of the total all-cause healthcare costs at 4L+ ($17,657 per PPPM) were related to outpatient visits followed by 27.6% ($8,376 per PPPM) attributed to pharmacy dispensing. Detailed treatment patterns and HRU data will be presented.
CONCLUSIONS: Despite therapeutic advances for patients with RRMM, healthcare costs increase substantially for patients who are triple-class exposed and initiate therapy in the 4L+ setting. These findings emphasize the need for innovative approaches that address economic burden in the current treatment landscape.
METHODS: We conducted a retrospective cohort study using the US-based Optum’s de-identified Clinformatics® Data Mart Database (Jan 2015-Mar 2024). Eligible patients were adults with RRMM following at least 3 prior lines of therapy (LOTs) who were triple-class exposed and initiated a new treatment regimen (index LOT). Descriptive statistics summarized treatment patterns and HRU measures. Total cost of care per patient per month (PPPM) was calculated.
RESULTS: A total of 289 patients who initiated 4L+ treatment were included. At index, the median age was 74 years (range: 25-90), and 52.2% were male. Racial distribution was 60.6% White, 16.6% Black, 3.1% Asian, and 20.1% unknown/missing. Patients had received median of 3 prior LOTs (range: 3-7). The median time from diagnosis to index LOT was 34 months and median follow up from index LOT was 8 months (IQR 3-15). Total costs PPPM rose from $21,336 in 1L to $30,331 in 4L+. Similarly, PPPM costs for all-cause hospitalizations increased from $2,670 in 1L to $3,814 in 4L+. More than half of the total all-cause healthcare costs at 4L+ ($17,657 per PPPM) were related to outpatient visits followed by 27.6% ($8,376 per PPPM) attributed to pharmacy dispensing. Detailed treatment patterns and HRU data will be presented.
CONCLUSIONS: Despite therapeutic advances for patients with RRMM, healthcare costs increase substantially for patients who are triple-class exposed and initiate therapy in the 4L+ setting. These findings emphasize the need for innovative approaches that address economic burden in the current treatment landscape.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE735
Topic
Clinical Outcomes, Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Oncology